✦ LIBER ✦

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

✍ Scribed by Susan H. Fox; Mark Kellett; A. Peter Moore; Alan R. Crossman; Jonathan M. Brotchie

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 149 KB
Volume: 17
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.1280

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.

📜 SIMILAR VOLUMES

Double-blind, placebo-controlled trial t

Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH

✍ Denis, Louis; Pagano, Francesco; Nonis, Atanasio; Robertson, Chris; Romano, Paol 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

BACKGROUND. Mepartricin, a semisynthetic polyene derivative with a favorable effect on urethro-prostatic function, was clinically evaluated, adopting the diagnostic and research criteria recommended by the First International Consultation on BPH. METHODS. A multicenter, randomized, double-blind, par

A double-blind placebo-controlled trial

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

✍ Olivier Vitton; Michael Gendreau; Judy Gendreau; Jay Kranzler; Srinivas G. Rao 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB 👁 1 views

Fibromyalgia syndrome is a systemic disorder of widespread pain which is thought to result from abnormal pain processing within the central nervous system. There are no currently approved treatments for this indication. Antidepressants appear, however, to be effective, especially those with an actio

Gabapentin in the treatment of fibromyal

Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial

✍ Lesley M. Arnold; Don L. Goldenberg; Sharon B. Stanford; Justine K. Lalonde; H. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective To assess the efficacy and safety of gabapentin in patients with fibromyalgia. ## Methods A 12‐week, randomized, double‐blind study was designed to compare gabapentin (1,200–2,400 mg/day) (n = 75 patients) with placebo (n = 75 patients) for efficacy and safety in treatin

Mirtazapine add-on therapy in the treatm

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

✍ Michael Berk; Clarissa S. Gama; Suresh Sundram; Harry Hustig; Les Koopowitz; Rus 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract ## Objective Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, parti

A double-blind placebo-controlled trial

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor

✍ Theresa A. Zesiewicz; Christopher L. Ward; Robert A. Hauser; Juan Sanchez-Ramos; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 6

Efficacy of nefazodone in the treatment

Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial

✍ Dora Wynchank; Michael Berk 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

## Abstract Many atypical antipsychotics show antagonism at both serotonergic and dopaminergic neurones and show fewer extrapyramidal side effects (EPS). Nefazodone blocks postsynaptic 5HT~2A~ receptors and weakly inhibits serotonin reuptake. This study aimed to elucidate the role of nefazodone in